UCLA doctors and researchers have been pioneers in immunotherapy and continue to be at the forefront of cancer treatments and discoveries in precision health.

Our dedicated team will work closely with you to explain requirements, details and preparation for your immunotherapy. We want to help you and your family receive the best care possible, and we will be there for you during and after treatment.
UCLA doctors and researchers have been pioneers in immunotherapy and continue to be at the forefront of cancer treatments and discoveries in precision health.

Our dedicated team will work closely with you to explain requirements, details and preparation for your immunotherapy. We want to help you and your family receive the best care possible, and we will be there for you during and after treatment.
CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy for patients with certain types of blood cancers. Immunotherapy is one of the most recent and promising fields in cancer research, reprogramming the immune system to help recognize and attack cancer cells. In CAR T-cell therapy, a type of white blood cell — known collectively as T cells — are genetically altered to attack cancer cells more specifically than chemotherapy.

CAR T-cell therapy requires one infusion and at least one week of hospitalization. The vast majority of patients treated with CAR T-cell therapy at UCLA experience a reduction in their cancer, and around half have ongoing long-term remissions after 18 months. UCLA also offers CAR T-cell therapy for pediatric patients with certain hematologic malignancies.

What to expect

Blood is collected and T cells are separated in a process called leukapheresis. Then, T cells are sent to a laboratory and modified into CAR T-cells through the addition of a chimeric antigen receptor (CAR) designed to recognize and attack cancer cells. These CAR T-cells are infused back into the body to begin attacking the cancer cells. Your care team will help you stay in close proximity to Ronald Reagan UCLA Medical Center for up to 30 days following your infusion and hospital stay.

Possible side effects

As with every type of cancer treatment, there are potential side effects. UCLA clinicians and staff participated in the clinical trials prior to U.S. Food and Drug Administration approval and have experience and expertise in the management of these risks.

Program highlights

UCLA is one of the first centers in the nation to offer CAR T-cell therapy. Our team consists of experts in leukemia, lymphoma and other blood cancers, and many of our physicians have led groundbreaking clinical trials.

Patients at UCLA benefit from the close collaboration between our world-class researchers at the David Geffen School of Medicine at UCLA and our expert physicians specializing in patient-focused care. Our multidisciplinary team of clinicians specialize in treating patients receiving CAR T-cell therapy and include hematologists/oncologists, pulmonologists and cardiologists.

UCLA is certified in both FDA-approved CAR T-cell therapy for adult and pediatric patients. Our team will work with your insurance company to expedite your treatment and ensure you receive the best care possible.
CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy for patients with certain types of blood cancers. Immunotherapy is one of the most recent and promising fields in cancer research, reprogramming the immune system to help recognize and attack cancer cells. In CAR T-cell therapy, a type of white blood cell — known collectively as T cells — are genetically altered to attack cancer cells more specifically than chemotherapy.

CAR T-cell therapy requires one infusion and at least one week of hospitalization. The vast majority of patients treated with CAR T-cell therapy at UCLA experience a reduction in their cancer, and around half have ongoing long-term remissions after 18 months. UCLA also offers CAR T-cell therapy for pediatric patients with certain hematologic malignancies.

What to expect

Blood is collected and T cells are separated in a process called leukapheresis. Then, T cells are sent to a laboratory and modified into CAR T-cells through the addition of a chimeric antigen receptor (CAR) designed to recognize and attack cancer cells. These CAR T-cells are infused back into the body to begin attacking the cancer cells. Your care team will help you stay in close proximity to Ronald Reagan UCLA Medical Center for up to 30 days following your infusion and hospital stay.

Possible side effects

As with every type of cancer treatment, there are potential side effects. UCLA clinicians and staff participated in the clinical trials prior to U.S. Food and Drug Administration approval and have experience and expertise in the management of these risks.

Program highlights

UCLA is one of the first centers in the nation to offer CAR T-cell therapy. Our team consists of experts in leukemia, lymphoma and other blood cancers, and many of our physicians have led groundbreaking clinical trials.

Patients at UCLA benefit from the close collaboration between our world-class researchers at the David Geffen School of Medicine at UCLA and our expert physicians specializing in patient-focused care. Our multidisciplinary team of clinicians specialize in treating patients receiving CAR T-cell therapy and include hematologists/oncologists, pulmonologists and cardiologists.

UCLA is certified in both FDA-approved CAR T-cell therapy for adult and pediatric patients. Our team will work with your insurance company to expedite your treatment and ensure you receive the best care possible.
CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy for patients with certain types of blood cancers. Immunotherapy is one of the most recent and promising fields in cancer research, reprogramming the immune system to help recognize and attack cancer cells. In CAR T-cell therapy, a type of white blood cell — known collectively as T cells — are genetically altered to attack cancer cells more specifically than chemotherapy.

CAR T-cell therapy requires one infusion and at least one week of hospitalization. The vast majority of patients treated with CAR T-cell therapy at UCLA experience a reduction in their cancer, and around half have ongoing long-term remissions after 18 months. UCLA also offers CAR T-cell therapy for pediatric patients with certain hematologic malignancies.

What to expect

Blood is collected and T cells are separated in a process called leukapheresis. Then, T cells are sent to a laboratory and modified into CAR T-cells through the addition of a chimeric antigen receptor (CAR) designed to recognize and attack cancer cells. These CAR T-cells are infused back into the body to begin attacking the cancer cells. Your care team will help you stay in close proximity to Ronald Reagan UCLA Medical Center for up to 30 days following your infusion and hospital stay.

Possible side effects

As with every type of cancer treatment, there are potential side effects. UCLA clinicians and staff participated in the clinical trials prior to U.S. Food and Drug Administration approval and have experience and expertise in the management of these risks.

Program highlights

UCLA is one of the first centers in the nation to offer CAR T-cell therapy. Our team consists of experts in leukemia, lymphoma and other blood cancers, and many of our physicians have led groundbreaking clinical trials.

Patients at UCLA benefit from the close collaboration between our world-class researchers at the David Geffen School of Medicine at UCLA and our expert physicians specializing in patient-focused care. Our multidisciplinary team of clinicians specialize in treating patients receiving CAR T-cell therapy and include hematologists/oncologists, pulmonologists and cardiologists.

UCLA is certified in both FDA-approved CAR T-cell therapy for adult and pediatric patients. Our team will work with your insurance company to expedite your treatment and ensure you receive the best care possible.
UCLA doctors and researchers have been pioneers in immunotherapy and continue to be at the forefront of cancer treatments and discoveries in precision health.

Our dedicated team will work closely with you to explain requirements, details and preparation for your immunotherapy. We want to help you and your family receive the best care possible, and we will be there for you during and after treatment.

UCLA CAR T-cell Therapy Program
888-ONC-UCLA (888-662-8252)
uclahealth.org/car-t-cell-therapy